<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03778645</url>
  </required_header>
  <id_info>
    <org_study_id>2018-995</org_study_id>
    <nct_id>NCT03778645</nct_id>
  </id_info>
  <brief_title>Adrenal Venous Sampling Via an Antecubital Approach</brief_title>
  <acronym>AVSA</acronym>
  <official_title>Adrenal Venous Sampling Via an Antecubital Approach: A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA.
      Right adrenal vein catheterization is often difficult due to unfavorable anatomy of the vein
      including small vein size, short length, caudal direction for the transfemoral approach, and
      rare drainage to the accessory hepatic vein. All of these factors limit the widespread use of
      this approach. Given that the right adrenal vein is angled caudally in most patients, AVS via
      an antecubital approach was performed since January 2012. The purpose of this multicenter
      retrospective study was to evaluate the safety and feasibility of AVS via the antecubital
      approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aldosteronism (PA) is recognized as the most common cause of secondary hypertension,
      with a prevalence of approximately 10% among unselected hypertensive populations. Subtype
      diagnosis is crucial because unilateral primary aldosteronism can be treated by laparoscopic
      adrenalectomy or open surgery, which may result in a cure or significant improvement of blood
      pressure, thus decreases the incidence of cardio-cerebrovascular complications. Currently,
      adrenal venous sampling (AVS) serves as the gold standard for subtyping of PA. Given that the
      right adrenal vein is angled caudally in most patients, AVS via an antecubital approach was
      performed since January 2012 at the Fuwai Hospital. So far, there have been more than fifteen
      hospitals to have some experience on AVS via antecubital approach with investigators' helps.
      The purpose of this multicenter retrospective study was to evaluate the safety and
      feasibility of AVS via the antecubital approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of bilateral adrenal sampling</measure>
    <time_frame>From January 1st 2012 to December 31st 2018</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The success rate of right adrenal sampling</measure>
    <time_frame>From January 1st 2012 to December 31st 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of left adrenal sampling</measure>
    <time_frame>From January 1st 2012 to December 31st 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adrenal vein ruptures occurring during AVS</measure>
    <time_frame>From January 1st 2012 to December 31st 2018</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Hyperaldosteronism</condition>
  <condition>Angiography</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adrenal Venous Sampling</intervention_name>
    <description>Adrenal Venous Sampling via an Antecubital Approach</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with primary aldosteronism underwent AVS via antecubital approach between
        January 1st 2012 and December 31st 2018 in medical centers (agreement of the principal
        investigator to participate to the AVSA) in China
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent of the principal investigator to participate to the data collection of
             patients with primary aldosteronism underwent AVS via antecubital approach

        Exclusion Criteria:

          -  Refusal of the principal investigator to participate to the AVSA Study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiongjing Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, National Center for Cardiovascular Disease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiongjing Jiang, MD</last_name>
    <phone>+861088322385</phone>
    <email>jxj103@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Dong, MD</last_name>
    <phone>+861088322385</phone>
    <email>donghui666@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiongjing Jiang, MD</last_name>
      <phone>86-1088322385</phone>
      <email>jxj103@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hui Dong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, MD</last_name>
      <phone>+86-023-89011552</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eighth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nan Jia, MD</last_name>
      <phone>86-0755-83982222</phone>
      <email>jiananchina@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianling Li, MD</last_name>
      <phone>+8607715359553</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Liu, MD</last_name>
      <phone>+96-037165586642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifei Dong, MD</last_name>
      <phone>86-0791-86297662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Xu, MD</last_name>
      <phone>86-021-64370045</phone>
      <email>jianzhongxv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an NO.3 Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Cheng, MD</last_name>
      <phone>86-029-61895566</phone>
      <email>chengkang2009@foxmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical College of Shihezi Universtiy</name>
      <address>
        <city>Shihezi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhitao Yan, MD</last_name>
      <phone>+86-0993-2859034</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 15, 2018</study_first_submitted>
  <study_first_submitted_qc>December 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Xiongjing Jiang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adrenal venous sampling</keyword>
  <keyword>Hyperaldosteronism</keyword>
  <keyword>Angiography</keyword>
  <keyword>Antecubital approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

